,

Rev Esp Quimioter 2023; June 2

Role of Hologic® Panther AptimaTM SARS-CoV-2 assay in the detection of SARS-CoV-2: screening or diagnostic technique?

CRISTINA GARCÍA-SALGUERO, LUIS VALLEJO, MERCERDES MARTÍNEZ-RODRÍGUEZ, ALBERTO DELGADO-IRIBARREN, ESTHER CULEBRAS

Published: 2 June 2023

http://www.doi.org/10.37201/req/135.2022

During the multiple waves of COVID-19 suffered all over the world, having a rapid and sensitive diagnostic test has become a priority for microbiology laboratories. The AptimaTM SARS-CoV-2 transcription-mediated amplification (TMA) assay running on the Panther system (Hologic) was presented as a very good option to cover this need. To evaluate this system, 570 respiratory samples were included in the study and were processed both by the Panther (Hologic) system and by qRT-PCR (Thermo Fisher Science, Waltham, USA), current assay for the diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A high number of false positives (n=76) was obtained with Panther system (Hologic), but the number of false positives decreases as the relative light units (RLU) value increases. These results show that this technique can be a good option for sample screening but checking for positive results should be mandatory, especially those with low RLU values.

Rev Esp Quimioter 2023; June 2 [Full-text PDF]


/por
,

Rev Esp Quimioter 2023; June 2

Tuberculous otitis media: A case presentation and review of european literature

MARÍA AGUILERA-FRANCO, ANA FRANCO-ACOSTA, ANA F YÉPEZ-NARANJO, JAVIER RODRÍGUEZ-GRANGER, ANTONIO SAMPEDRO, JOSÉ MARÍA NAVARRO-MARI

Published: 2 June 2023

http://www.doi.org/10.37201/req/011.2023

Tuberculous otitis media (TOM) is a rare affectation in our environment that represents a challenge in its diagnosis due to the non-specific symptoms that it usually presents. This paper presents our experience in the diagnosis of a case of TOM in a 66-year-old woman with hearing loss and chronic otorrhea of more than 6 months of evolution that did not respond to conventional treatments. In addition, a review of the cases published in the last 20 years (2000-2022) in countries of the European Union (EU) is carried out. The most common symptoms were otorrhea (n=43; 100%), hearing loss (n=37; 86.05%), eardrum perforation (n=19; 44.18%), facial paralysis (n=12, 27,91%) and ear pain (n=13; 30,23%). The most used sample for diagnosis was the biopsy obtained by mastoidectomy (n=34; 79.06%). All patients were given antituberculous therapy for a mean duration of 8.11 months (range, 6-12 months). The most frequent aftereffect was hearing loss (n=28; 65.12%). TOM should be included in the differential diagnosis of chronic suppurative otitis, since early diagnosis and treatment reduce the probability of suffering irreversible sequelae.

Rev Esp Quimioter 2023; June 2 [Texto completo PDF]


/por
,

Rev Esp Quimioter 2023; June 1

Neisseria meningitidis, más allá de la afectación del sistema nervioso central

HANSANEE FERNÁNDEZ MANANDU, ESTÍBALIZ MOLINA ITURRITZA, IRENE SAN JOSÉ MUÑIZ, MIREN URRESTARAZU LARRAÑAGA

Published: 1 June 2023

LETTER TO THE EDITOR

http://www.doi.org/10.37201/req/015.2023

Rev Esp Quimioter 2023; June 1 [Texto completo PDF]


/por
,

Rev Esp Quimioter 2023; June 1

Neumonía asociada a derrame parapneumónico en paciente inmunocompetente causado por Bordetella bronchiseptica

DOMINGO FERNÁNDEZ VECILLA, MARY PAZ ROCHE MATHEUS, GOTZON IGLESIAS HIDALGO, MIREN JOSEBE UNZAGA BARAÑANO, JOSÉ LUIS DÍAZ DE TUESTA DEL ARCO

Published: 1 June 2023

LETTER TO THE EDITOR

http://www.doi.org/10.37201/req/006.2023

Rev Esp Quimioter 2023; June 1 [Texto completo PDF]


/por
,

Rev Esp Quimioter 2023; May 31

Use of ceftaroline in complex central nervous system infections

ALICIA ALONSO ÁLVAREZ, EFRÉN SÁNCHEZ VIDAL, LUCÍA RAMOS MERINO, DOLORES SOUSA REGUEIRO, JOAQUÍN SERRANO AREBA, ENRIQUE MÍGUEZ REY, PEDRO LLINARES MODÉJAR

Published: 17 May 2023

LETTER TO THE EDITOR

http://www.doi.org/10.37201/req/143.2022

Rev Esp Quimioter 2023; May 31  [Full-text PDF]

/por
,

Rev Esp Quimioter 2023; May 31

Antimicrobial stewardship program in an Intensive Care Unit: A retrospective observational analysis of the results 15 months after its implementation

DAVID PÉREZ-TORRES, LUIS MARIANO TAMAYO-LOMAS, MARTA DOMÍNGUEZ-GIL GONZÁLEZ, ROSENDO ALMENDROS-MUÑOZ, MARÍA AURORA SACRISTÁN-SALGADO, ESTHER GONZÁLEZ-GONZÁLEZ, JOSÉ ÁNGEL BEREZO-GARCÍA, CRISTINA DÍAZ-RODRÍGUEZ, ISABEL CANAS-PÉREZ, BELÉN LORENZO-VIDAL, JOSÉ MARÍA EIROS-BOUZA

Published: 31 May 2023

http://www.doi.org/10.37201/req/142.2022

Objective. We aim to evaluate the adherence rate to an Antimicrobial Stewardship Program (ASP) in an Intensive Care Unit (ICU), and to assess its effect on the use of antibiotics, quality indicators and clinical outcomes.
Patients and methods. Retrospective description of the interventions proposed by the ASP. We compared antimicrobial use, quality and safety indicators in an ASP versus a non-ASP period. The study was performed in a polyvalent ICU of a medium-size University Hospital (600 beds). We studied patients admitted to the ICU for any cause during the ASP period, provided that a microbiological sample aiming to diagnose a potential infection has been drawn, or antibiotics have been started. We elaborated and registered of non-mandatory recommendations to improve antimicrobial prescription (audit and feedback structure) and its registry during the ASP period (15 months, October 2018-December 2019). We compared indicators in a period with ASP (April-June 2019) and without ASP (April-June 2018).
Results. We issued 241 recommendations on 117 patients, 67% of them classified as de-escalation type. The rate of adherence to the recommendations was high (96.3%). In the ASP period, the mean number of antibiotics per patient (3.3±4.1 vs 2.4±1.7, p=0.04) and the days of treatment (155 DOT/100 PD vs 94 DOT/100 PD, p <0.01) were reduced. The implementation of the ASP did not compromise patient safety or produce changes in clinical outcomes.
Conclusion. The implementation of an ASP is widely accepted in the ICU, reducing the consumption of antimicrobials, without compromising patient safety.

Rev Esp Quimioter 2023; May 31 [Texto completo PDF]


/por
,

Rev Esp Quimioter 2023; May 17

Bacteriemia por Solobacterium moorei en paciente con sinusitis       

IZASKUN ALEJO-CANCHO, ANA GUAL-DE-TORRELLA, RAQUEL VIELBA POSTIGO, IÑIGO PEREZ ABRAGUIN, LAURA REDONDO FARIAS, MARÍA JOSÉ LOPEZ DE GOIKOETXEA

Published: 17 May 2023

LETTER TO THE EDITOR

http://www.doi.org/10.37201/req/141.2022

Rev Esp Quimioter 2023; May 17  [Full-text PDF]


/por
,

Rev Esp Quimioter 2023; May 16

Two cases of Prevotella oris causing serious pleuropulmonary infections       

DOMINGO FERNÁNDEZ VECILLA, MARY PAZ ROCHE MATHEUS, GOTZON IGLESIAS HIDALGO, ESTÍBALIZ UGALDE ZÁRRAGA, MIREN JOSEBE UNZAGA BARAÑANO, JOSÉ LUIS DÍAZ DE TUESTA DEL ARCO

Published: 16 May 2023

LETTER TO THE EDITOR

http://www.doi.org/10.37201/req/001.2023

Rev Esp Quimioter 2023; May 16  [Full-text PDF]


/por
,

Rev Esp Quimioter 2023; 36(3): 314-316

Absceso por Clostridium perfringens en usuario de drogas por vía parenteral: slamming       

ALFREDO MALDONADO-BARRUECO, DAVID GRANDIOSO-VAS, JULIO GARCÍA-RODRÍGUEZ, INMACULADA QUILES-MELERO

Published: 15 May 2023

LETTER TO THE EDITOR

http://www.doi.org/10.37201/req/103.2022

Rev Esp Quimioter 2023; 36(3): 314-316  [Texto completo PDF]


/por
,

Rev Esp Quimioter 2023; May 8

High macrolides and fluoroquinolones resistance rate in Mycoplasma genitalium in southern Tenerife

CRISTIAN MATEO LEÓN, DIEGO GARCÍA MARTÍNEZ DE ARTOLA, BERTA PINO-CALM

Published: 8 May 2023

http://www.doi.org/10.37201/req/014.2023

Introduction. Mycoplasma genitalium (MG) is a recognized sexually transmitted pathogen. Increasing resistance to main lines of treatment (macrolides and quinolones) justifies a genetic study of mutations to improve cure rates.
Material and methods. A total of 8,508 samples from April 2018 to July 2022 were processed using AllplexTM STI Essential Assay. In MG positive cases 23S rRNA V domain, gyrA and parC genes were studied. Mutations detected were checked to assess their clinical significance and medical records were reviewed to obtain demographic and treatment information.
Results. Resistance study was performed on 92 samples (65 men and 27 women). In relation to the genotypic study, 28 patients presented mutations to macrolides (30.43%). Most common was A2059G (18.48%). For quinolones, 5 patients (5.43%) had clinically relevant mutations in parC gene. Of note was a patient with G295 mutation in gyrA associated with G248T in parC. Thirty subjects underwent a test of cure (TOC). Azithromycin was the most common empirical regimen and moxifloxacin the main alternative.
Conclusions. High rate of resistance in our environment evidences the need for targeted therapy by genotypic study of macrolide resistance, supported by the detection of mutations in parC and gyrA to predict quinolones susceptibility and the use of TOC to evaluate treatment response

Rev Esp Quimioter 2023; May 8 [Texto completo PDF]


/por